Daiichi Sankyo announced that its inhaled antiviral Inavir (laninamivir) was approved in Japan as a treatment for patients with influenza A and B viruses.
The drugmaker noted that a single dose of the long-acting neuraminidase inhibitor has shown to be as effective for the treatment of influenza as a five-day course of Roche's Tamiflu (oseltamivir).
-Reference Articles
Daiichi Sankyo receives approval to manufacture and market Inavir influenza antiviral inhalant for treatment in Japan - (Daiichi Sankyo)
Daiichi Sankyo's new flu drug Inavir approved in Japan - (NASDAQ)
*Published in "First Word"
No comments:
Post a Comment